Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotec) disclosed a Next Day Disclosure Return dated 29 April 2026 detailing its latest on-market share repurchase on the Hong Kong Stock Exchange.

Key transaction • Date: 29 April 2026 • Shares repurchased: 112,500 H-shares (0.0497% of total ordinary shares in issue) • Price range: HKD 22.24–22.58 per share • Aggregate consideration: HKD 2.52 million

Outstanding share capital (29 April 2026) • H-shares in issue: 35.93 million (no treasury shares held) • A-shares in issue: 190.20 million; treasury A-shares: 3.85 million • Combined ordinary share capital: 226.13 million shares

Buy-backs pending cancellation Including the latest purchase, 692,000 H-shares acquired between 23 March and 29 April 2026 await formal cancellation. These were bought at volume-weighted average prices ranging from HKD 21.55 to HKD 22.76.

Mandate utilisation • Shareholder mandate granted: 10 June 2025, authorising repurchase of up to 3.91 million shares. • Cumulative shares repurchased under the mandate: 3.29 million, representing 8.41% of the issued share base on the mandate date. • Remaining capacity under the mandate: approximately 0.62 million shares.

Post-repurchase restrictions Under Hong Kong Listing Rules, Haohai Biotec is restricted from issuing new shares or selling treasury shares until 29 May 2026, 30 days after the latest buy-back.

All repurchases were executed in accordance with Hong Kong Stock Exchange regulations and relevant domestic rules, as confirmed by the company’s Board Secretary Tian Min.